Key Moments
404 ‒ Mental health beyond neurotransmitters: hormones in psychiatry, psychedelic therapies, & more
Peter Attia MDWant to know something specific about what's covered?
We've already dissected every moment. Ask and we will deliver (with timestamps).
Key Moments
Psychiatry is moving beyond neurotransmitters to explore hormones, metabolism, and inflammation, revealing that current treatments may not fully restore life's richness, and modern life itself may be a significant contributor to mental health challenges.
Key Insights
The traditional psychiatric model focuses on symptom reduction rather than the restoration of the full human experience, which can leave patients feeling ambivalent even with successful symptom alleviation.
SSRI antidepressants, while effective for millions, can paradoxically decrease dopamine and norepinephrine, potentially leading to a "blunted" feeling or exacerbating conditions like ADHD.
Bipolar depression responds differently to antidepressants than unipolar depression, with the former potentially triggering mood cycling, agitation, or mixed states if not treated with mood stabilizers first.
Estradiol is a critical brain hormone that acts as a pleiotropic regulator of multiple neurotransmitter systems, influencing mood, cognition, and anxiety, and its withdrawal can significantly impact brain function in both men and women.
Hypothyroidism, even with TSH within the "normal" range but with suboptimal free T4 or free T3, can manifest as depression and may respond well to thyroid hormone supplementation.
While psychedelic therapies like ketamine and psilocybin show promise for rapid relief of acute distress, their long-term efficacy is variable, and their unpredictable nature necessitates caution and careful supervision due to potential negative experiences and risks.
Beyond neurotransmitters: A shift in psychiatric focus
Dr. Linus Abrams, a psychiatrist with nearly 35 years of experience, discusses his pivot after three decades from a traditional psychopharmacology focus to integrating endocrinology, metabolism, inflammation, and circadian biology into his understanding of mental health. He observes that while psychiatry aims to reduce symptoms, it often falls short of restoring the "full human experience" that makes life worthwhile. This dissatisfaction, even in successful cases of symptom reduction, inspired his deeper investigation into broader biological systems. Abrams highlights the unique challenge in psychiatry of lacking measurable biomarkers, relying instead on subjective patient interaction and hypothesis-driven treatment, where even adverse drug responses can offer valuable diagnostic information.
The paradox of SSRIs and the complexity of mood regulation
The conversation delves into the widely known Selective Serotonin Reuptake Inhibitors (SSRIs), noting their historical significance and broad impact. While effective for millions, Abrams explains that by increasing serotonin, SSRIs can sometimes decrease dopamine and norepinephrine. This can lead to a "blunted" feeling or exacerbate symptoms in individuals with conditions like ADHD. He clarifies that Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) offer a different balance, potentially mitigating some of these effects. The distinction between SSRIs and SNRIs is presented not as a strict dichotomy but a continuum, with different drugs emphasizing serotonin, norepinephrine, or both. Abrams notes that while SSRIs are often associated with depression, they are frequently more effective for anxiety disorders, and drugs like Lexapro (escitalopram) are commonly used for rumination, OCD, and anxiety, even if not primarily for major depression.
Navigating bipolar disorder: The critical distinction in treatment
A significant portion of the discussion focuses on the crucial differentiation between unipolar and bipolar depression. Abrams emphasizes that patients often present with symptoms of bipolar disorder without knowing their diagnosis. He explains that bipolar II disorder, characterized by hypomania rather than full mania, can be adaptive, with individuals using its drive for remarkable achievements. However, a key distinction emerges in how bipolar depression responds to treatment. While unipolar depression typically responds favorably to antidepressants, bipolar depression can lead to adverse reactions, including mood cycling, agitation, or mixed states. Abrams stresses the importance of mood stabilizers like lamotrigine or lithium as first-line treatment for bipolar depression, as antidepressants alone can be the "wrong drug" and potentially destabilize the patient. The underlying mechanisms of these mood stabilizers, such as affecting sodium channels or influencing cellular pathways, are briefly touched upon.
Estradiol: The brain's vital regulator
The conversation highlights the profound role of estradiol, a key hormone for both men and women, in brain function. Abrams describes estradiol as a "constitutive pleiotropic multi-system regulator of neurotransmitters and neural circuits." It influences serotonin, dopamine, GABA, acetylcholine, NMDA, and glutamate systems. Unlike psychotropics that amplify signals, estradiol modulates the conditions within which neurotransmission occurs, acting upstream and influencing gene transcription for neurotransmitter synthesis. Receptors for estradiol are present in the brain, and its effects are deeply embedded in neuronal activity. The withdrawal of estradiol, such as during menopause, can lead to significant challenges in mood regulation, cognition, and anxiety, impacting multiple domains of function. The variability in how women experience these changes is attributed to a combination of genetic factors affecting receptor sensitivity and broader adaptive capacities influenced by lifestyle and stress.
Thyroid function: An often-missed contributor to depression
The discussion shifts to the thyroid axis, with Abrams pointing out that many individuals with "normal" TSH levels, particularly those in the upper half of the normal range (e.g., 2.5-5.0 mIU/L), may still have suboptimal thyroid function contributing to their depression. He emphasizes the importance of measuring free T4 and free T3 levels, considering free T4 as a key biomarker. Low free T4 in a patient with depression is seen as a signal for potential thyroid supplementation. While hyperthyroidism is more commonly associated with anxiety, hypothyroidism is frequently linked to depressive symptoms. Abrams notes that he prioritizes symptom relief over solely relying on lab values when titrating thyroid hormone treatment, sometimes using T3 monotherapy for treatment-resistant depression, cautiously managing dosage and timing to avoid insomnia.
The HPA axis and chronic stress: A modern challenge
The hypothalamic-pituitary-adrenal (HPA) axis and cortisol's role in stress response are discussed. Abrams identifies hyperarousal, a state evolved for acute survival, as a common maladaptive chronic condition in modern society. Unlike other hormonal systems, there isn't a simple pill to directly block excessive cortisol. Instead, the approach involves addressing the root causes of chronic stress, whether they stem from caregiving burdens, work-related issues, or unmanaged medical conditions. Abrams explains that he doesn't use an "endocrine-centric vocabulary" with patients but rather discusses these stressors in practical, common-sense terms, framing cortisol as a signal rather than the primary problem.
Psychedelics and neuroplasticity: Promise and peril
The conversation explores the emerging field of psychedelic therapies, including ketamine and psilocybin. Ketamine, an NMDA receptor antagonist, is noted for its rapid induction of neuroplasticity and potential for quickly reducing suicidal ideation, serving as a "bridge" to other treatments. However, its long-term efficacy can be variable, and its use is time-consuming, expensive, and inconvenient. Both Peter Attia and Dr. Abrams share personal experiences with psychedelics that ranged from profoundly negative and "devastating" to transformative and deeply empathetic. They caution that individual responses are unpredictable, highlighting the "Russian roulette" aspect of recreational use and the need for strict clinical supervision. While optimism exists for future therapeutic applications, particularly for PTSD (MDMA) and end-of-life depression (psilocybin), the unpredictable nature and potential for adverse effects remain significant concerns.
Mentioned in This Episode
●Supplements
●Companies
●Drugs & Medications
●Studies Cited
●Concepts
●People Referenced
Common Questions
The speaker believes that traditional psychopharmacology aims at symptom reduction but often fails to restore the full human experience that makes life worthwhile, leading to patient ambivalence even with objective symptom improvement. This often results in patients struggling to adhere to ongoing treatment regimens.
Topics
Mentioned in this video
Selective Serotonin Reuptake Inhibitor, a class of antidepressants that primarily target serotonin modulation. Often causes blunted emotions and can decrease dopamine.
Monoamine Oxidase Inhibitors, an older class of antidepressants that could be dangerous if combined with tyramine-containing foods.
An older class of antidepressants with more severe side effects and potential lethality in overdose compared to SSRIs.
Generic name for Zoloft, an SSRI that also mildly blocks dopamine reuptake.
An SNRI, brand name Effexor.
An SNRI, brand name Pristiq.
A mood stabilizer effective for treating bipolar depression, potentially by changing sodium channels.
A class of drugs mentioned in the context of modern metabolic challenges.
A drug that indirectly increases endogenous testosterone by tricking the brain into producing more LH and FSH, but often leads to patient dissatisfaction despite good lab numbers.
A synthetic oral analog of allopregnanolone, used for postpartum depression.
An atypical antipsychotic (brand name Abilify) used as an augmentation strategy for treatment-resistant depression.
An atypical antipsychotic, used as an augmentation strategy for treatment-resistant depression.
Serotonin and Norepinephrine Reuptake Inhibitor, a class of drugs that balance serotonin and norepinephrine, potentially causing less cognitive dulling than pure SSRIs.
The first SSRI, also known as Prozac, developed by Eli Lilly to block serotonin reuptake.
Generic name for Lexapro, considered a very pure SSRI.
A mood stabilizer, effective for treating depression and elevated moods in bipolar disorder.
A hormone that tells the body to make more endogenous testosterone, administered peripherally.
An isomer of Clomiphene, also used to indirectly increase endogenous testosterone.
An intravenous infusion used for postpartum depression, a synthetic analog of allopregnanolone.
Thyroid hormone used in some cases for treatment-resistant depression, can be given in immediate-release form up to 25 micrograms twice daily.
An antidepressant also known as Wellbutrin, used in cases of unipolar depression.
An atypical antipsychotic (brand name Rexulti) used as an augmentation strategy for treatment-resistant depression.
An NMDA receptor antagonist and dissociative anesthetic used for difficult-to-treat depression, often as a bridge to other solutions due to its short-lived effects.
A classic psychedelic that can induce neuroplasticity and therapeutic effects, but with unpredictable experiences.
A psychedelic also known as an empathogen, which increases empathy and may have a strong role in certain types of PTSD.
Also known as Arimidex, a drug that prevents the aromatization of testosterone into estradiol.
A hormone described as a constitutive, pleotropic, multi-system regulator of neurotransmitters and neural circuits, crucial for cognitive function, mood, and anxiety.
A primary hormone for men, where losses can lead to dulling and impaired dopamine-mediated functions; a prodrug for estradiol.
A hormone that rises in the second half of the menstrual cycle and crashes after no implantation, with its derivative allopregnanolone linked to PMDD and postpartum depression.
A neurosteroid derived from progesterone, linked to PMDD and postpartum depression.
A thyroid hormone value considered more important than TSH for diagnosing thyroid deficiency affecting mental health.
A chronic low-grade depressive tendency, distinct from major depressive episodes.
The male version of menopause, characterized by a gradual and insidious decline in testosterone.
A thyroid hormone value important for diagnosing thyroid deficiency and used as supplementation for treatment-resistant depression.
More from Peter Attia MD
View all 340 summaries
51 min403 ‒ Peptides: separating scientific promise from marketing hype
148 min402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample
118 minBuilding strength and muscle mass: optimize training & nutrition for longevity (AMA #71 rebroadcast)
121 min397 - Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, & emerging treatments
Ask anything from this episode.
Save it, chat with it, and connect it to Claude or ChatGPT. Get cited answers from the actual content — and build your own knowledge base of every podcast and video you care about.
Get Started Free